Please login to the form below

Not currently logged in
Email:
Password:

Roche safety fears over RA treatment

Roche has suspended Ocrelizumab treatment in its rheumatoid arthritis (RA) development programme following serious safety risks

Roche and research partner Biogen Idec have suspended the use of monoclonal antibody Ocrelizumab in their rheumatoid arthritis (RA) development programme following serious safety risks.

These risks included "serious and opportunistic infections, some of which were fatal" according to a statement from Roche.

The decision to suspend development comes after recommendation from the independent Ocrelizumab RA & Lupus Data and Safety Monitoring Board (DSMB) who assessed several Roche studies involving RA, known as SCRIPT, FEATURE, FILM and STAGE, as well as two trials focusing on Lupus.

It was concluded by the DSMB that the safety risk of using Ocrelizumab "outweighs the benefits observed in these specific patient populations at this time".

Dr Hal Barron, executive vice president and chief medical officer at Roche confirmed the progamme's suspension: "Patient safety is of the utmost importance in all of our drug development programmes. In light of the DSMB recommendations we have decided to suspend Ocrelizumab treatment in the RA clinical development programme."

Issues involving the RA development programme have already been faced by Roche, with the FILM study, which involved MTX-naïve RA patients, having previously been placed on hold following an assessment of benefit to risk in this specific RA patient population.

The BELONG study, involving lupus nephritis patients, had also previously been suspended due to "serious and opportunistic infection signals".

Roche have said "a detailed analysis of all of the data will be conducted to help further inform the future of the Ocrelizumab RA clinical programme."

The company also confirmed that the evaluation of Ocrelizumab for relapsing remitting multiple sclerosis (RRMS) in a phase II study is still ongoing.


 

8th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics